+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hypertension Drug Market Research Report by Therapy, by Analysis, by Distribution, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 4904908
  • Report
  • July 2021
  • Region: Global
  • 199 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Hypertension Drug Market will Grow to USD 34.50 Billion by 2026, at a CAGR of 8.54%

FEATURED COMPANIES

  • AstraZeneca Plc.
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Lupin Limited
  • Novartis AG
The Global Hypertension Drug Market size was estimated at USD 21.09 Billion in 2020 and expected to reach USD 22.82 Billion in 2021, at a Compound Annual Growth Rate (CAGR) 8.54% to reach USD 34.50 Billion by 2026.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Hypertension Drug to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Therapy, the Hypertension Drug Market was studied across Alpha Blockers, Angiotensin Converting Enzyme Inhibitor, Angiotensin Receptor Blockers, Beta Blockers Vasodilators, Calcium Channel Blockers, Diuretics, and Renin Inhibitors.
  • Based on Type, the Hypertension Drug Market was studied across Combination Therapy and Mono Therapy.
  • Based on Analysis, the Hypertension Drug Market was studied across Pulmonary Hypertension Drugs and Systemic Hypertension Drugs.
  • Based on Distribution, the Hypertension Drug Market was studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, the Hypertension Drug Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Hypertension Drug Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Hypertension Drug Market, including AstraZeneca Plc., Bayer AG, Boehringer Ingelheim, Daiichi – Sankyo, F. Hoffmann-La Roche Ltd, Gilead, GlaxoSmithKline plc, Johnson & Johnson Ltd., Lupin Limited, Merck & Co., Novartis AG, Pfizer Inc., Ranbaxy Laboratories Limited, Sanofi S.A, and Takeda Pharmaceutical Company.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Hypertension Drug Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Hypertension Drug Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Hypertension Drug Market?
4. What is the competitive strategic window for opportunities in the Global Hypertension Drug Market?
5. What are the technology trends and regulatory frameworks in the Global Hypertension Drug Market?
6. What is the market share of the leading vendors in the Global Hypertension Drug Market?
7. What modes and strategic moves are considered suitable for entering the Global Hypertension Drug Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca Plc.
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Lupin Limited
  • Novartis AG
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Therapy Outlook
3.4. Type Outlook
3.5. Analysis Outlook
3.6. Distribution Outlook
3.7. Region Outlook
3.8. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in awareness related to complications associated with hypertension
5.1.1.2. Increasing prevalence of hypertension
5.1.1.3. Rise in geriatric population
5.1.2. Restraints
5.1.2.1. Low awareness of the antihypertensive drugs
5.1.2.2. Unavailability of hypertension drugs in remote areas
5.1.3. Opportunities
5.1.3.1. Advances in pharmacologic treatment of hypertension
5.1.3.2. Growing initiatives by private and government organizations for R&D
5.1.3.3. Increasing focus on development of new drugs
5.1.4. Challenges
5.1.4.1. Increased concern of side-effects of treatment options
5.1.4.2. Rising number of alternate generic drugs
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Hypertension Drug Market, by Therapy
6.1. Introduction
6.2. Alpha Blockers
6.3. Angiotensin Converting Enzyme Inhibitor
6.4. Angiotensin Receptor Blockers
6.5. Beta Blockers Vasodilators
6.6. Calcium Channel Blockers
6.7. Diuretics
6.8. Renin Inhibitors

7. Hypertension Drug Market, by Type
7.1. Introduction
7.2. Combination Therapy
7.3. Mono Therapy

8. Hypertension Drug Market, by Analysis
8.1. Introduction
8.2. Pulmonary Hypertension Drugs
8.3. Systemic Hypertension Drugs

9. Hypertension Drug Market, by Distribution
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy

10. Americas Hypertension Drug Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Hypertension Drug Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Thailand

12. Europe, Middle East & Africa Hypertension Drug Market
12.1. Introduction
12.2. France
12.3. Germany
12.4. Italy
12.5. Netherlands
12.6. Qatar
12.7. Russia
12.8. Saudi Arabia
12.9. South Africa
12.10. Spain
12.11. United Arab Emirates
12.12. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion

14. Company Usability Profiles
14.1. AstraZeneca Plc.
14.2. Bayer AG
14.3. Boehringer Ingelheim
14.4. Daiichi – Sankyo
14.5. F. Hoffmann-La Roche Ltd
14.6. Gilead
14.7. GlaxoSmithKline plc
14.8. Johnson & Johnson Ltd.
14.9. Lupin Limited
14.10. Merck & Co.
14.11. Novartis AG
14.12. Pfizer Inc.
14.13. Ranbaxy Laboratories Limited
14.14. Sanofi S.A
14.15. Takeda Pharmaceutical Company

15. Appendix
15.1. Discussion Guide
15.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL HYPERTENSION DRUG MARKET SIZE, 2020 VS 2026 (USD BILLION)
FIGURE 2. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2020 (USD BILLION)
FIGURE 3. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2020 (USD BILLION)
FIGURE 4. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2020 (USD BILLION)
FIGURE 5. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2020 (USD BILLION)
FIGURE 6. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY REGION, 2020 (USD BILLION)
FIGURE 7. GLOBAL HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 8. GLOBAL HYPERTENSION DRUG MARKET: MARKET DYNAMICS
FIGURE 9. GLOBAL HYPERTENSION DRUG MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 10. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2020 VS 2026 (%)
FIGURE 11. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2020 VS 2026 (USD BILLION)
FIGURE 12. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2026
FIGURE 13. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ALPHA BLOCKERS, 2018-2026 (USD BILLION)
FIGURE 14. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 15. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ANGIOTENSIN CONVERTING ENZYME INHIBITOR, 2018-2026 (USD BILLION)
FIGURE 16. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ANGIOTENSIN CONVERTING ENZYME INHIBITOR, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 17. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, 2018-2026 (USD BILLION)
FIGURE 18. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 19. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY BETA BLOCKERS VASODILATORS, 2018-2026 (USD BILLION)
FIGURE 20. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY BETA BLOCKERS VASODILATORS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 21. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, 2018-2026 (USD BILLION)
FIGURE 22. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 23. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DIURETICS, 2018-2026 (USD BILLION)
FIGURE 24. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DIURETICS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 25. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY RENIN INHIBITORS, 2018-2026 (USD BILLION)
FIGURE 26. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY RENIN INHIBITORS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 27. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2020 VS 2026 (%)
FIGURE 28. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2020 VS 2026 (USD BILLION)
FIGURE 29. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2026
FIGURE 30. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2026 (USD BILLION)
FIGURE 31. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 32. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY MONO THERAPY, 2018-2026 (USD BILLION)
FIGURE 33. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY MONO THERAPY, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 34. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2020 VS 2026 (%)
FIGURE 35. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2020 VS 2026 (USD BILLION)
FIGURE 36. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2026
FIGURE 37. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY PULMONARY HYPERTENSION DRUGS, 2018-2026 (USD BILLION)
FIGURE 38. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY PULMONARY HYPERTENSION DRUGS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 39. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY SYSTEMIC HYPERTENSION DRUGS, 2018-2026 (USD BILLION)
FIGURE 40. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY SYSTEMIC HYPERTENSION DRUGS, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 41. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2020 VS 2026 (%)
FIGURE 42. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2020 VS 2026 (USD BILLION)
FIGURE 43. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2026
FIGURE 44. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2026 (USD BILLION)
FIGURE 45. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 46. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ONLINE PHARMACY, 2018-2026 (USD BILLION)
FIGURE 47. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 48. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY RETAIL PHARMACY, 2018-2026 (USD BILLION)
FIGURE 49. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2020 VS 2026 (USD BILLION)
FIGURE 50. AMERICAS HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 51. ARGENTINA HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 52. BRAZIL HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 53. CANADA HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 54. MEXICO HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 55. UNITED STATES HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 56. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 57. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 58. CHINA HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 59. INDIA HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 60. INDONESIA HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 61. JAPAN HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 62. MALAYSIA HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 63. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 64. SINGAPORE HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 65. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 66. THAILAND HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 67. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 68. FRANCE HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 69. GERMANY HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 70. ITALY HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 71. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 72. QATAR HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 73. RUSSIA HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 74. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 75. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 76. SPAIN HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 77. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 78. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 79. GLOBAL HYPERTENSION DRUG MARKET: FPNV POSITIONING MATRIX
FIGURE 80. GLOBAL HYPERTENSION DRUG MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 81. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL HYPERTENSION DRUG MARKET, BY TYPE

List of Tables
TABLE 1. GLOBAL HYPERTENSION DRUG MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 4. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY THERAPY, 2018-2026 (USD BILLION)
TABLE 5. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2026 (USD BILLION)
TABLE 6. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ANGIOTENSIN CONVERTING ENZYME INHIBITOR, BY REGION, 2018-2026 (USD BILLION)
TABLE 7. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2026 (USD BILLION)
TABLE 8. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY BETA BLOCKERS VASODILATORS, BY REGION, 2018-2026 (USD BILLION)
TABLE 9. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2026 (USD BILLION)
TABLE 10. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DIURETICS, BY REGION, 2018-2026 (USD BILLION)
TABLE 11. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY RENIN INHIBITORS, BY REGION, 2018-2026 (USD BILLION)
TABLE 12. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY TYPE, 2018-2026 (USD BILLION)
TABLE 13. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2026 (USD BILLION)
TABLE 14. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY MONO THERAPY, BY REGION, 2018-2026 (USD BILLION)
TABLE 15. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ANALYSIS, 2018-2026 (USD BILLION)
TABLE 16. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY PULMONARY HYPERTENSION DRUGS, BY REGION, 2018-2026 (USD BILLION)
TABLE 17. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY SYSTEMIC HYPERTENSION DRUGS, BY REGION, 2018-2026 (USD BILLION)
TABLE 18. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 19. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2026 (USD BILLION)
TABLE 20. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2026 (USD BILLION)
TABLE 21. GLOBAL HYPERTENSION DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2026 (USD BILLION)
TABLE 22. AMERICAS HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 23. ARGENTINA HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 24. BRAZIL HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 25. CANADA HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 26. MEXICO HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 27. UNITED STATES HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 28. ASIA-PACIFIC HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 29. AUSTRALIA HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 30. CHINA HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 31. INDIA HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 32. INDONESIA HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 33. JAPAN HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 34. MALAYSIA HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 35. PHILIPPINES HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 36. SINGAPORE HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 37. SOUTH KOREA HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 38. THAILAND HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 39. EUROPE, MIDDLE EAST & AFRICA HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 40. FRANCE HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 41. GERMANY HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 42. ITALY HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 43. NETHERLANDS HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 44. QATAR HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 45. RUSSIA HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 46. SAUDI ARABIA HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 47. SOUTH AFRICA HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 48. SPAIN HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 49. UNITED ARAB EMIRATES HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 50. UNITED KINGDOM HYPERTENSION DRUG MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 51. GLOBAL HYPERTENSION DRUG MARKET: SCORES
TABLE 52. GLOBAL HYPERTENSION DRUG MARKET: BUSINESS STRATEGY
TABLE 53. GLOBAL HYPERTENSION DRUG MARKET: PRODUCT SATISFACTION
TABLE 54. GLOBAL HYPERTENSION DRUG MARKET: RANKING
TABLE 55. GLOBAL HYPERTENSION DRUG MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 56. GLOBAL HYPERTENSION DRUG MARKET: MERGER & ACQUISITION
TABLE 57. GLOBAL HYPERTENSION DRUG MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 58. GLOBAL HYPERTENSION DRUG MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 59. GLOBAL HYPERTENSION DRUG MARKET: INVESTMENT & FUNDING
TABLE 60. GLOBAL HYPERTENSION DRUG MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 61. GLOBAL HYPERTENSION DRUG MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • AstraZeneca Plc.
  • Bayer AG
  • Boehringer Ingelheim
  • Daiichi – Sankyo
  • F. Hoffmann-La Roche Ltd
  • Gilead
  • GlaxoSmithKline plc
  • Johnson & Johnson Ltd.
  • Lupin Limited
  • Merck & Co.
  • Novartis AG
  • Pfizer Inc.
  • Ranbaxy Laboratories Limited
  • Sanofi S.A
  • Takeda Pharmaceutical Company
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll